Newsfeeds - Spark Newswire

1 minute read

BioMarin Expects EMA’s CHMP Opinion In 1H 2022 For Its Hemophilia A Gene Therapy, FDA Resubmission In 2Q’22

Today, 10:58 AM

The European Medicines Agency (EMA) has validated BioMarin Pharmaceutical Inc’s (NASDAQ:BMRN) marketing application seeking approval for hemophilia A gene therapy, valoctocogene…

BMRN

1 minute read

AMMO Announces The European Medicines Agency Has Validated Co.’s Marketing Authorization Application For Valoctocogene Roxaparvovec

By Bill Haddad

Today, 10:58 AM

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the European Medicines Agency (EMA) validated the Company's Marketing Authorization Application (MAA) for its investigational gene therapy,

BMRN

3 minute read

BioMarin Announces 12 Presentations At International Society On Thrombosis And Haemostasis (ISTH) 2021 Virtual Congress

By Benzinga Newsdesk

Today, 10:58 AM

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced three oral presentations and nine poster presentations related to valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with

BMRN

1 minute read

EMA’s Advisory Committee Backs Approval Of BioMarin’s Dwarfism Candidate

By Vandana Singh

Today, 10:58 AM

European Medical Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the…

BMRN

1 minute read

BioMarin Receives Positive CHMP Opinion In Europe For Vosoritide For Treatment Of Children With Achondroplasia From Age 2 Until Growth Plates Close

By Bill Haddad

Today, 10:58 AM

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for vosoritide, a once daily

BMRN

Latest news

BioMarin Expects EMA’s CHMP Opinion In 1H 2022 For Its Hemophilia A Gene Therapy, FDA Resubmission In 2Q’22

AMMO Announces The European Medicines Agency Has Validated Co.’s Marketing Authorization Application For Valoctocogene Roxaparvovec

BioMarin Announces 12 Presentations At International Society On Thrombosis And Haemostasis (ISTH) 2021 Virtual Congress

EMA’s Advisory Committee Backs Approval Of BioMarin’s Dwarfism Candidate

BioMarin Receives Positive CHMP Opinion In Europe For Vosoritide For Treatment Of Children With Achondroplasia From Age 2 Until Growth Plates Close